Brind.

AbbVie, Amgen, and MIT Join Yosemite's Cancer-Focused Fund

1 report, 1 independent Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

On November 4, 2026, AbbVie, Amgen, and MIT joined Yosemite's fund as Limited Partners. John Doerr is also listed as a Limited Partner in the fund. notes that Yosemite is devoted to cancer-focused investing.

From fortune.com

Why it matters

Some supportBrind's analysis of the reports

The investment supports Yosemite's mission to fund cancer-focused startups. John Doerr, who founded Yosemite after spinning out of Emerson Collective in 2023, is focused on advancing medicine to make cancer less intractable.

From fortune.com

Who's involved

  • AbbVieLimited Partner in Yosemite's fund
  • AmgenLimited Partner in Yosemite's fund
  • MITLimited Partner in Yosemite's fund
  • John DoerrLimited Partner and founder of Yosemite
  • Emerson CollectiveSocial change organization from which John Doerr spun out

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • AbbVieSpeculative

    AbbVie might see changes in capital allocation due to its direct investment commitment in Yosemite's fund.

  • AmgenSpeculative

    Amgen might see changes in capital allocation due to its direct investment commitment in Yosemite's fund.

  • MITSpeculative

    MIT might see changes in investment costs or capital allocation due to its direct investment commitment in Yosemite's fund.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped